SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

YIELD10 Bioscience, Inc. – ‘10-Q’ for 3/31/22 – ‘EX-32.1’

On:  Wednesday, 5/11/22, at 4:10pm ET   ·   For:  3/31/22   ·   Accession #:  1121702-22-22   ·   File #:  1-33133

Previous ‘10-Q’:  ‘10-Q’ on 11/10/21 for 9/30/21   ·   Next:  ‘10-Q’ on 8/10/22 for 6/30/22   ·   Latest:  ‘10-Q’ on 5/15/24 for 3/31/24   ·   4 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 5/11/22  YIELD10 Bioscience, Inc.          10-Q        3/31/22   59:4.5M

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    462K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     21K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     21K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     19K 
10: R1          Cover                                               HTML     70K 
11: R2          Condensed Consolidated Statements of Operations     HTML     81K 
                Unaudited                                                        
12: R3          Condensed Consolidated Balance Sheets Unaudited     HTML    117K 
13: R4          Condensed Consolidated Balance Sheets               HTML     34K 
                (Parenthetical)                                                  
14: R5          Condensed Consolidated Statements of Comprehensive  HTML     43K 
                Loss Unaudited                                                   
15: R6          Condensed Consolidated Statements of Cash Flows     HTML     92K 
                Unaudited                                                        
16: R7          Condensed Consolidated Statements of Stockholders'  HTML     73K 
                Equity                                                           
17: R8          Accounting Policies                                 HTML     48K 
18: R9          Nature of Business and Basis of Presentation        HTML     28K 
19: R10         Basic and Diluted Net Loss Per Share                HTML     27K 
20: R11         Investments                                         HTML     37K 
21: R12         Fair Value Measurements                             HTML     50K 
22: R13         Accrued Expenses                                    HTML     26K 
23: R14         Stock-Based Compensation                            HTML     34K 
24: R15         Leases                                              HTML     42K 
25: R16         Commitments and Contingencies                       HTML     27K 
26: R17         Geographic Information                              HTML     39K 
27: R18         Capital Stock and Warrants                          HTML     44K 
28: R19         Accounting Policies (Policies)                      HTML     90K 
29: R20         Accounting Policies (Tables)                        HTML     38K 
30: R21         Basic and Diluted Net Loss Per Share (Tables)       HTML     26K 
31: R22         Investments (Tables)                                HTML     36K 
32: R23         Fair Value Measurements (Tables)                    HTML     47K 
33: R24         Accrued Expenses (Tables)                           HTML     26K 
34: R25         Stock-Based Compensation (Tables)                   HTML     33K 
35: R26         Leases (Tables)                                     HTML     39K 
36: R27         Geographic Information (Tables)                     HTML     36K 
37: R28         Capital Stock and Warrants (Tables)                 HTML     45K 
38: R29         ACCOUNTING POLICIES - Additional Information        HTML     42K 
                (Details)                                                        
39: R30         ACCOUNTING POLICIES - Schedule of Cash And          HTML     26K 
                Restricted Cash (Details)                                        
40: R31         Nature of Business and Basis of Presentation        HTML     20K 
                (Details)                                                        
41: R32         Basic and Diluted Net Loss Per Share (Details)      HTML     27K 
42: R33         Investments (Details)                               HTML     30K 
43: R34         FAIR VALUE MEASUREMENTS - Assets and Liabilities    HTML     45K 
                Measured at Fair Value on a Recurring Basis                      
                (Details)                                                        
44: R35         Accrued Expenses (Details)                          HTML     30K 
45: R36         Stock-Based Compensation (Details)                  HTML     68K 
46: R37         Stock-Based Compensation - RSU Activity (Details)   HTML     28K 
47: R38         LEASES - Narrative (Details)                        HTML     31K 
48: R39         LEASES - Maturity Analysis of Lease Liabilities     HTML     38K 
                (Details)                                                        
49: R40         LEASES - Quantitative Disclosure of Lease Costs     HTML     32K 
                (Details)                                                        
50: R41         Commitments and Contingencies (Details)             HTML     25K 
51: R42         Geographic Information (Details)                    HTML     31K 
52: R43         CAPITAL STOCK AND WARRANTS - Narrative (Details)    HTML     37K 
53: R44         CAPITAL STOCK AND WARRANTS - Schedule Of Warrants   HTML     38K 
                Issuance (Details)                                               
54: R45         CAPITAL STOCK AND WARRANTS - Schedule of Common     HTML     25K 
                Stock Reserved For Future Issuance (Details)                     
57: XML         IDEA XML File -- Filing Summary                      XML    101K 
55: XML         XBRL Instance -- yten-20220331_htm                   XML    972K 
56: EXCEL       IDEA Workbook of Financial Reports                  XLSX     66K 
 6: EX-101.CAL  XBRL Calculations -- yten-20220331_cal               XML    137K 
 7: EX-101.DEF  XBRL Definitions -- yten-20220331_def                XML    314K 
 8: EX-101.LAB  XBRL Labels -- yten-20220331_lab                     XML   1.04M 
 9: EX-101.PRE  XBRL Presentations -- yten-20220331_pre              XML    585K 
 5: EX-101.SCH  XBRL Schema -- yten-20220331                         XSD     92K 
58: JSON        XBRL Instance as JSON Data -- MetaLinks              291±   416K 
59: ZIP         XBRL Zipped Folder -- 0001121702-22-000022-xbrl      Zip    175K 


‘EX-32.1’   —   Certification — §906 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  

EXHIBIT 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
    In connection with the Quarterly Report on Form 10-Q of Yield10 Bioscience, Inc. (the “Company”) for the quarter ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Oliver Peoples, President, Chief Executive Officer and Principal Executive Officer of the Company and Charles B. Haaser, Chief Accounting Officer and Principal Financial and Accounting Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to our knowledge that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

2.The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

    This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be “filed” for any purpose whatsoever.
 
/s/ OLIVER PEOPLES
Oliver Peoples
President and Chief Executive Officer
(Principal Executive Officer)
/s/ CHARLES B. HAASER
Charles B. Haaser
Chief Accounting Officer
(Principal Financial and Accounting Officer)

1

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:5/11/228-K
For Period end:3/31/224
 List all Filings 


3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/24/23  YIELD10 Bioscience, Inc.          424B5                  1:587K
11/14/22  YIELD10 Bioscience, Inc.          10-Q        9/30/22   60:4.8M
 8/10/22  YIELD10 Bioscience, Inc.          10-Q        6/30/22   59:4.7M


1 Previous Filing that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/25/22  YIELD10 Bioscience, Inc.          10-K       12/31/21   83:9.4M
Top
Filing Submission 0001121702-22-000022   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 17, 10:33:22.3am ET